Charles & Colvard (CTHR) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Proxy solicitation by Duc Pham, a significant shareholder, seeking election to the Board at the 2025 Annual Meeting, citing the need for leadership change to maximize shareholder value.
Shareholders will vote to elect five directors from three slates: Pham, Company Nominees, and RiverStyx Nominees, using a universal proxy card.
Pham's campaign is motivated by persistent revenue declines, GAAP losses, and poor stock performance, with a focus on operational turnaround and customer-centric strategy.
Voting matters and shareholder proposals
Election of five directors for one-year terms, with shareholders able to vote for any combination of nominees from all slates.
Additional proposals include ratification of the independent auditor, advisory approval of executive compensation, and the frequency of future say-on-pay votes.
Voting instructions and procedures detailed, with emphasis on using the BLUE universal proxy card for all votes.
Board of directors and corporate governance
Current Board consists of five members; all seats up for election.
Pham seeks to bring an independent, data-driven, and design-focused perspective to the Board.
If elected, Pham would be in the minority unless joined by RiverStyx Nominees; implementation of his proposals is not guaranteed.
Latest events from Charles & Colvard
- Court-ordered annual meeting set for October 13, 2025, with limited agenda and board elections.CTHR
Proxy Filing1 Dec 2025 - Director nominations by a shareholder were invalidated; Board to recommend elections at the Annual Meeting.CTHR
Proxy Filing1 Dec 2025 - Proxy contest seeks to replace four directors to address financial and governance concerns.CTHR
Proxy Filing1 Dec 2025 - Shareholders face a contested Board election amid calls for leadership change and strategic overhaul.CTHR
Proxy Filing1 Dec 2025 - Riverstyx seeks board control with three nominees and challenges a dilutive stock issuance.CTHR
Proxy Filing1 Dec 2025 - Board recommends its director slate, annual say-on-pay, and cost-saving measures amid restructuring.CTHR
Proxy Filing1 Dec 2025 - FY2024 saw a 27% sales decline, $14.4M loss, and major liquidity risks for Charles & Colvard.CTHR
Q4 202430 Sep 2025